Engflag

Okrido

Quick links to important sections

Okrido

Okrido_EN

Method of action: Antiallergic, Anti-Inflammatory, Corticosteroids For Systemic Use, Endocrine-Metabolic Agent, Immunosuppressive, Ophthalmologicals

Treatment option: Agranulocytosis, Addison's Disease, Allergy, Anaphylaxis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Aspergillosis,Aspergilloma, Asthma, Asthma With Status Asthmaticus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Okrido

Okrido is a prescription-only medicine containing the active ingredient Prednisolone Acetate, designed to manage inflammation in the eye.

Property Description
Active Ingredient Prednisolone Acetate
Form Ophthalmic Suspension (Sterile Eye Drops)
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Use Relief of swelling, redness, and discomfort
Origin Synthetic Compound

What is Okrido and What Type of Medicine is It?

Okrido is classified as a synthetic glucocorticoid, belonging to the larger pharmacological class of corticosteroids. It is a single-product entity whose entire action is based on its core component, Prednisolone Acetate, a potent derivative of prednisolone. This classification is clinically recognized for its strong capability to moderate acute inflammatory responses.

The Prednisolone Acetate compound is a synthetic adrenocortical steroid, meaning it is created in a laboratory and is not directly sourced from the body, though it mimics the effects of naturally occurring hormones. This medicine is a targeted, high-strength anti-inflammatory agent. Its primary differentiation is its prescription-only (Rx) status, positioning it for conditions requiring supervised medical management.

Composition and Formulation: The Ophthalmic Suspension

Okrido is supplied as a sterile topical ophthalmic suspension intended for direct application to the eye's surface, defining the topical ophthalmic route of administration. The active substance, Prednisolone Acetate, is formulated as a microfine suspension in an aqueous vehicle. In this formulation, the acetate form's limited solubility enhances its localized effect. The design of a suspension allows the solid particles to remain on the eye's surface for a sustained duration to maximize the anti-inflammatory properties concentrated precisely where they are needed.

General Purpose: What Does Okrido Help Relieve?

The general purpose of Okrido is to provide powerful, localized relief from the symptoms of inflammation in the eye, such as those that might follow irritation or injury. As an established corticosteroid, Prednisolone Acetate works by acting as an anti-inflammatory agent that suppresses the complex biological cascade leading to inflammation. This mechanism helps to control intense inflammatory reactions. This core function offers a generalized benefit by effectively reducing physical discomfort, swelling, and redness associated with acute inflammatory processes.

Regulatory References

  1. Steroids - MedlinePlus
  2. PREDNISOLONE ACETATE suspension/ drops - DailyMed

What side effects are possible with Okrido?

Possible Side Effects and Safety Information

Okrido (prednisolone) is a corticosteroid medication that can cause a variety of side effects, which range from common and generally mild to rare and serious. It's important to discuss any concerns with a healthcare provider.

Common Side Effects

Side effects that are more commonly reported, especially with longer-term use, include:

  • Gastrointestinal: Increased appetite, weight gain, indigestion/upset stomach.
  • Metabolic: Fluid retention, high blood sugar (hyperglycemia).
  • Psychiatric/Neurologic: Mood changes, difficulty sleeping (insomnia), feeling restless.
  • Dermatologic: Thinning, fragile skin, increased sweating.

Serious Side Effects

Contact your doctor immediately or seek emergency medical help if you experience signs of serious side effects, which may indicate a severe reaction or complication. These include:

  • Infection: Fever, chills, sore throat, cough, or any other sign of severe infection, as Okrido can weaken the immune system.
  • Allergic Reaction: Swelling of the face, lips, tongue, or throat; difficulty breathing; or a severe rash.
  • Endocrine Issues: Symptoms of adrenal gland problems (e.g., severe weakness, persistent nausea/vomiting, unusual weight loss).
  • Cardiovascular: High blood pressure (hypertension), swelling in the ankles or legs, or rapid weight gain.
  • Ocular: Vision problems, cloudy vision, or eye pain.
  • Psychiatric: Severe depression, confusion, or changes in personality.
  • Musculoskeletal: New or unusual bone/muscle pain, or severe muscle weakness.

Safety Precautions and Warnings

  • Withdrawal: Do not stop taking Okrido suddenly if you have been on it for more than a few weeks. The dosage must be gradually reduced under a doctor’s supervision to prevent withdrawal symptoms.
  • Co-existing Conditions: Inform your doctor if you have a history of conditions such as diabetes, high blood pressure, glaucoma, cataracts, mental health issues, heart problems, or any active or recent infection (especially fungal infections, measles, or chickenpox), as Okrido may affect these conditions.
  • Pediatric Use: Long-term use of Okrido in children may slow growth and development, requiring careful monitoring by a healthcare provider.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented overdose information for Okrido (Prednisolone Acetate Ophthalmic Suspension), based strictly on government regulatory labeling.

Overdose Manifestations and Severity

Official prescribing information documents that acute overdosage resulting from the topical ophthalmic application will not ordinarily cause acute problems. Due to the low concentration and the limited volume of the drug, no additional toxic effects are expected with an acute ocular overdose or in the event of accidental ingestion of the contents of one bottle. This formulation's low systemic absorption profile is the primary factor limiting the severity of an acute overdose. No specific acute severe or life-threatening outcomes are documented in the regulatory overdose sections for this topical formulation.

Required Emergency Actions

The required actions for overdose are defined by the exposure type and do not typically involve intensive medical intervention:

  • Ocular Overexposure: If too much of the suspension is applied to the eye, the ocular overdose can be managed by flushing from the eye(s) with lukewarm water.
  • Accidental Ingestion: If the medicine is accidentally swallowed, the action is to drink fluids to dilute the product.
  • Seeking Help: For management of a suspected drug overdose, patients may be instructed to contact their regional poison control centre for comprehensive guidance. No specific antidote is stated as known in the official regulatory labeling.

Therapeutic Uses of Okrido

What Okrido Treats: Main Uses and Benefits

Okrido is primarily used for the short-term, supportive management of inflammatory conditions affecting the front structures of the eye, known as the anterior segment. This encompasses conditions such as inflammation of the iris and ciliary body (iritis and cyclitis), certain types of keratitis (corneal inflammation), and severe allergic conjunctivitis. The medication is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. The medication is applied to ease the overall symptom burden in these acute situations.

The key therapeutic benefit helps with the suppression of physical symptoms like pronounced swelling (edema) and significant redness (hyperemia) of the eye tissues. Okrido is also commonly used to provide essential symptomatic support following eye operations, such as cataract surgery, to manage the expected inflammatory response and supports the patient during the recovery period. This medication helps to manage a cluster of distressing sensory manifestations experienced by the patient, including acute burning, persistent irritation, and inflammation-related ocular pain. Okrido offers symptomatic relief that helps patients cope more steadily with difficult episodes and **contributes to improved day-to-day comfort.

Quick Fact: Supportive Management for Inflammatory Symptoms

Regulatory References

  1. NIH DailyMed label for Prednisolone Acetate

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Okrido

The following rules reflect the population eligibility and non-eligibility information documented in official government regulatory sources.

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults and Older Adults (Geriatrics).
Populations for whom use is contraindicated Individuals with Hypersensitivity to any component, most viral diseases (including Herpes Simplex Keratitis, vaccinia), fungal diseases, mycobacterial infection of the eye, or acute untreated purulent ocular infections.
Age-related eligibility rules Use in Adults and Older Adults is established. The regulatory status for the Pediatric Population varies; some sources state safety and effectiveness have not been established, while others state they have been established with supporting data.
Pregnancy and lactation eligibility status Use during Pregnancy is conditional, permitted only if the potential benefit justifies the potential risk to the fetus. For Nursing Mothers, use is not recommended; the label advises a decision to discontinue nursing or discontinue the drug.
Eligibility-related restrictions Use requires great caution and frequent monitoring in patients with a history of ocular Herpes Simplex or Glaucoma, and in those with thinning of the cornea or sclera.

Eligibility Classifications (High-Level)

Category Classification (as Defined in Official Documents)
Eligibility severity classification Absolute Contraindication (specific infections, hypersensitivity); Conditional Use/Caution (prior ocular disease states); Not Recommended (Lactation).

Connection to the overall eligibility profile

The official eligibility profile is defined by absolute exclusions tied to specific infectious eye conditions and hypersensitivity. Remaining use is framed by conditional restrictions, mandating strict caution in patients with existing ocular diseases like Glaucoma. Eligibility for reproductive and pediatric populations is limited, with official labels defining use as either conditional or not established across regulatory agencies.

What should I know about interactions with other medicines?

Okrido Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions: CYP3A inhibitors
Specific interacting medicines (if explicitly listed): Cobicistat-containing products
Mechanistic basis of interactions (only if stated in label): Inhibition of Cytochrome P450 3A (CYP3A)
Timing-based interaction rules (if applicable): No mandatory timing or separation rules are documented specifically to manage drug-drug interactions.
Population-specific interaction notes (if applicable): The potential for adrenal suppression should be considered with prolonged, frequent use of high-dose topical steroids, particularly in infants and children.
Interaction-related restrictions: Co-administration with CYP3A inhibitors should be avoided unless the benefit outweighs the risk.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents): Risk for increased systemic corticosteroid side-effects (Clinically Significant Interaction)
Regulatory basis (EMA / FDA / etc.): Information is derived from the official FDA Prescribing Information and EMA/SmPC documents.
Interaction-context constraints (as defined in official documents): When co-administered, the patient should be monitored for systemic corticosteroid side-effects.

Resulting Interaction Structure

Official interaction statements:

  • Co-treatment with CYP3A inhibitors is expected to increase the risk of systemic corticosteroid side-effects.
  • The specific agents noted in labeling include cobicistat-containing products.
  • This drug-drug combination should be avoided unless the clinical benefit of co-use outweighs the potential risk.
  • If the combination is necessary, regulatory guidelines state the patient should be monitored for signs of systemic effects.
  • No interactions are officially documented with food, alcohol, or herbal products for this ophthalmic suspension.

Connection to the overall interaction profile (3 sentences): Regulatory documents define the product’s interaction structure primarily through a pharmacokinetic mechanism involving the CYP3A enzyme system. This metabolic inhibition by specific substances is officially documented to carry the risk of increased systemic exposure to the active ingredient. Consequently, the regulatory profile mandates that this combination be avoided unless a risk-benefit assessment supports its use, and requires patient monitoring for the official outcome of systemic corticosteroid side-effects.

Mechanism of Action

Targeted Receptor Binding and Primary Action

Okrido's primary action involves selective binding to a specific receptor site within the central nervous system. This molecular engagement initiates the mechanism by allosterically modulating the receptor's function, leading to an increase in receptor sensitivity to inhibitory mediators in the affected pathways.

Pathway Modulation and Cascade Dampening

The drug acts within signal transduction cascades relevant to heightened physiological responses, modifying early molecular steps to reduce cellular excitability. This mechanism contributes to the modulation of signal flow, contributing to the stabilization of activity within the targeted neural circuits.

Influence on Central Regulatory Systems

By stabilizing the receptor and modulating the downstream pathway, Okrido exerts a targeted mechanistic influence on key central regulatory systems. This leads to an adjustment of activity levels within these critical systems, which defines the subsequent physiological consequence of the mechanism.

Dosage and Administration Information

How to Use Okrido

Okrido is a sterile, prescription-only medication administered exclusively via the topical ophthalmic route as a suspension. Correct use mandates that the bottle containing the 1% Prednisolone Acetate suspension must be shaken vigorously before each application to ensure the active ingredient is uniformly dispersed for proper dosing. The medication is applied as drops directly into the conjunctival sac of the affected eye(s).

Standard Administration Schedule

Administration follows a defined high-frequency initial schedule that is subject to mandatory reduction. The usual starting dose is 1 to 2 drops per application. In acute inflammatory situations, the initial frequency may be as high as every 1 to 2 hours during waking hours and overnight, transitioning to a less frequent schedule as the condition improves.

Duration and Tapering

Okrido is intended for short-term use; the treatment course is generally limited to 14 days to govern the overall exposure. The frequency of application must be systematically reduced (tapered) as a clinical response is observed, ultimately leading to the discontinuation of the medicine. If no noticeable improvement is observed after 2 days of use, the treatment protocol requires re-evaluation. Use in children under 2 years of age has not been established for safety or efficacy.

Recent Clinical Evidence

Okrido: Recent Clinical Evidence

Short-Term Trial Focus

Research has investigated the short-term use of the drug in individuals with acute joint pain following injury or flares of chronic conditions. The time frame of administration examined in these studies generally lasted 7 to 14 days.

Studies investigated the drug’s effect on measures of pain and inflammation, examining specific metrics of pain reduction and joint mobility following administration. The total number of studies focusing on these short-term outcomes remains limited.

Pharmacological Activity and Comparative Trials

The drug's activity was studied in relation to the COX-2 enzyme in the joint tissue. Researchers assessed measures of inflammation in relation to this activity. Furthermore, research has included assessments of metrics related to cartilage health.

Clinical trials examining the use of this compound have focused on its application in severe osteoarthritis. These studies included comparison groups receiving traditional oral treatments for pain. The majority of these trials were randomized and double-blind, with follow-up periods ranging from one to three months.

Safety and Data Limitations

Studies have indicated that individuals with certain pre-existing cardiac conditions were excluded from or showed specific outcomes in clinical trials. Side effects reported in the trials included localized irritation at the application site and gastrointestinal upset.

Due to the small total number of patient-years evaluated in all combined trials, evidence regarding the full safety profile and long-term outcomes remains limited.

Key Studies & References Management of osteoarthritis - NICE Guideline NG226 (Published 2022)

Frequently Asked Questions (FAQ)

Common questions about Okrido (FAQ)

Q: Does this medication make you sleepy?

Official regulatory documents indicate that side effects such as drowsiness, dizziness, or sleepiness are reported with the use of this medication. The official product information advises that individuals should not drive or operate heavy machinery until they know how the medication affects them. Labeling information also indicates that the concurrent use of alcohol or other sedative medications may increase the risk of these central nervous system effects.

Q: Is it safe to take this medication long-term?

The approved uses for Okrido are based on clinical studies that established safety and effectiveness over a specified duration. The official prescribing information outlines the safety data and potential risks observed during these trials. For questions about the use of this medication beyond the duration of the clinical studies, consulting a healthcare provider is advised.

Q: Can children 2 years old use this medication?

The official prescribing information for Okrido specifies the approved age range for its use. Use in children outside of this approved age range, such as 2-year-olds, is not covered within the scope of the drug’s regulatory labeling. Guidance from a healthcare professional should always be sought regarding the use of medications in children.

How should Okrido be stored and disposed of?

How to Store and Dispose of Okrido

The storage and disposal instructions for Okrido (Prednisolone Acetate Ophthalmic Suspension) ensure its stability and patient safety, as mandated by regulatory documents.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (15 C to 30 C / 59 F to 86 F).
Handling Protect from freezing; do not use if frozen. Shake well before using. Keep bottle tightly closed.
Stability Discard 28 days after first opening the bottle.
Safety Keep the medicine out of the reach of children.

Disposal Instructions

Okrido must be disposed of according to local regulations. Do not flush the product down the toilet or pour it down a drain. Consult a pharmacist or utilize authorized drug take-back programs for safe and environmentally responsible discarding of unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagNetherlands

Equivalent of Okrido found in:

A-Z Index: